Xavier Leroy on his appointment as CEO of GIO Therapeutics! Xavier Leroy appointed as CEO of GIO Therapeutics GPCR Events, Meetings, and Webinars NOW!

Xavier Leroy, Dr. Brian Arey, and Dr. J. Silvio Gutkind.

Xavier Leroy for his new role as CEO of GIO Therapeutics Dr.

During periods of treatment-emergent hypogammaglobulinemia, BsAb recipients had higher infection rates During periods of non-neutropenia, CAR-T recipients had a lower risk (HR 0.44, 95%CI 0.21-0.93, P = 0.032 Our results also suggest a higher infection risk during periods of hypogammaglobulinemia with BsAb, and

During this period and her doctoral thesis, she has deepened the regulatory mechanisms of GPCR signaling In her postdoctoral period, she has participated in the identification and characterization of proteins

During my Scholar period I have published or contributed in 38 published scientific work mainly in the